Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
For the full year,net loss reported to Rs 73.80 crore in the year ended March 2026 as against net loss of Rs 17.97 crore during the previous year ended March 2025. Sales declined 1.61% to Rs 1421.59 crore in the year ended March 2026 as against Rs 1444.85 crore during the previous year ended March 2025.
OneSource Specialty Pharma announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world's most significant semaglutide markets.
The milestone reflects a closely integrated development and manufacturing model. Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from OneSource's US FDA-approved flagship facility in Bengaluru.
The approval follows a recent tentative approval in the United States supported by OneSource, further reinforcing the company's growing presence in complex peptide-based injectable programs and its ability to support global partners across highly regulated markets.
Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: “We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets. Our partnership with Orbicular highlights our role in enabling global commercialization through strong, collaborative ecosystems.”
OneSource Specialty Pharma announced that its partner Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.
The partnership is designed to ensure reliable and scalable commercial supply from OneSource's US-FDA approved flagship manufacturing facility in Bengaluru.
Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities.”
OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic® (Semaglutide Injection).
OneSource is the contract development and manufacturing organization (CDMO) partner for this product. This milestone highlights a closely integrated development-to-submission model: Orbicular led the product development and technical program for this complex peptide, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the U.S. market filing. The collaboration is designed to ensure reliable commercial supply from OneSource's US-FDA approved flagship site in Bangalore.
Neeraj Sharma, CEO & MD, OneSource Speciality Pharma, speaking on the development, said: “We are pleased to announce that our partner Orbicular, along with its front-end partner (the ANDA holder), has received tentative approval for a generic version of Ozempic® (Semaglutide Injection). This milestone reflects Orbicular's scientific expertise and OneSource's CDMO capabilities, supported by our US-FDA approved manufacturing site.”
Polycab India Ltd, OneSource Specialty Pharma Ltd, TD Power Systems Ltd and Hexaware Technologies Ltd are among the other losers in the BSE's 'A' group today, 10 March 2026.
KEI Industries Ltd crashed 6.69% to Rs 4469.6 at 14:45 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 80647 shares were traded on the counter so far as against the average daily volumes of 16060 shares in the past one month.
Polycab India Ltd tumbled 6.46% to Rs 7697.35. The stock was the second biggest loser in 'A' group.On the BSE, 58988 shares were traded on the counter so far as against the average daily volumes of 26478 shares in the past one month.
OneSource Specialty Pharma Ltd lost 3.91% to Rs 1455.8. The stock was the third biggest loser in 'A' group.On the BSE, 1.32 lakh shares were traded on the counter so far as against the average daily volumes of 41678 shares in the past one month.
TD Power Systems Ltd slipped 3.68% to Rs 814.3. The stock was the fourth biggest loser in 'A' group.On the BSE, 1.19 lakh shares were traded on the counter so far as against the average daily volumes of 92891 shares in the past one month.
Hexaware Technologies Ltd dropped 3.37% to Rs 441.55. The stock was the fifth biggest loser in 'A' group.On the BSE, 44759 shares were traded on the counter so far as against the average daily volumes of 1.72 lakh shares in the past one month.
The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region.
Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state of-the-art integrated Biologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based on sales1, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.
SBFC Finance Ltd, Syngene International Ltd, JSW Energy Ltd and Avantel Ltd are among the other losers in the BSE's 'A' group today, 27 January 2026.
OneSource Specialty Pharma Ltd tumbled 18.35% to Rs 1169.8 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.17 lakh shares were traded on the counter so far as against the average daily volumes of 6142 shares in the past one month.
SBFC Finance Ltd lost 11.37% to Rs 90.05. The stock was the second biggest loser in 'A' group.On the BSE, 26.8 lakh shares were traded on the counter so far as against the average daily volumes of 2.51 lakh shares in the past one month.
Syngene International Ltd crashed 10.03% to Rs 488.15. The stock was the third biggest loser in 'A' group.On the BSE, 6.61 lakh shares were traded on the counter so far as against the average daily volumes of 36060 shares in the past one month.
JSW Energy Ltd dropped 8.49% to Rs 437.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 9.32 lakh shares were traded on the counter so far as against the average daily volumes of 91637 shares in the past one month.
Avantel Ltd pared 7.26% to Rs 126.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 4.58 lakh shares were traded on the counter so far as against the average daily volumes of 1.07 lakh shares in the past one month.